Treatment of human respiratory syncytial virus infected Balb/C mice with the proteasome inhibitor bortezomib (Velcade, PS-341) results in increased inflammation and mortality

Toxicology
Christopher LupferM K Pastey

Abstract

Human Respiratory Syncytial Virus (HRSV) is an important pathogen and is associated with mortality in the young, old, and immuno-compromised. Due to the lack of effective therapeutic antivirals or a vaccine, there is a critical need for continued research in this field. Here we tested the ability of the FDA approved proteasome inhibitor bortezomib to inhibit HRSV in vitro and in vivo. We observed significant inhibition of HRSV replication in Vero cells at bortezomib concentrations from 20 to 40 ng/ml. Bortezomib was well tolerated in mice when administered intranasally at concentrations of < or = 0.3 mg/kg or intraperitoneally at 1.0 mg/kg. However, treatment of HRSV-infected mice with doses as low as 0.01 mg/kg resulted in increased pulmonary inflammation and mortality compared to mock treated-infected control animals. Examination of cytokine expression levels from lungs of bortezomib treated HRSV-infected mice revealed an increase in G-CSF, IL-6, MCP-1, and RANTES levels and a decrease in total IL-12 compared to mock treated-infected control animals. These data indicate that treatment with bortezomib during HRSV infection may alter the immune response and could potentially create a risk for patients treated with bortezomib in...Continue Reading

References

Oct 17, 2001·Journal of Virology·R N HartyM J Schnell
Jan 9, 2003·JAMA : the Journal of the American Medical Association·William W ThompsonKeiji Fukuda
May 14, 2004·Journal of Virology·Juan Martin-SerranoPaul D Bieniasz
Dec 30, 2004·The Journal of Cell Biology·Juan Martin-SerranoPaul D Bieniasz
Feb 16, 2007·American Journal of Hematology·Adedayo A OnitiloSeth Fagbemi
Jul 25, 2007·Traffic·Juan Martin-Serrano
Aug 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrizia ZappasodiAlessandro Corso
Jul 12, 2008·Cancer Science·Masashi FukayamaHiroshi Uozaki
Sep 4, 2008·Clinical Lymphoma & Myeloma·Seok Jin KimUNKNOWN Korean Multiple Myeloma Working Party
Jun 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonAnthony A Amato
Sep 23, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Marcio Nucci, Elias Anaissie

❮ Previous
Next ❯

Citations

Oct 15, 2014·Biomolecules·Cathal MahonElah Pick
Nov 16, 2019·Journal of Leukocyte Biology·Hui-Wen YaoSheng-Min Hsu
Oct 7, 2020·Biochemical and Biophysical Research Communications·Xu ZhangYuehong Zheng

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.